Opendata, web and dolomites

TK-NEO SIGNED

Personalized Cancer Immunotherapy through DNA-EP vaccines

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 TK-NEO project word cloud

Explore the words cloud of the TK-NEO project. It provides you a very rough idea of what is the project "TK-NEO" about.

metastatic    tests    vc    licensing    completion    right    customized    immunity    carry    chemotherapeutic    validation    sme    vaccine    market    reduce    proven    manufacturing    clinical    form    co    patented    applicability    fold    instrument    safety    locally    disease    tk    ncvs    tumour    authorization    constituted    client    cancer    additional    release    5m    neo    tumor    immune    trials    vaccination    ncv    perfect    confirm    week    alternative    ep    takis    final    patients    respect    synthesis    lung    therapeutic    mice    first    dna    combining    patient    zero    pricing    surgery    financing    protecting    strategy    investment    maintenance    sequencing    company    boosting    underwent    neoantigen    medicine    mou    melanoma    tumors    solid    electroporation    stage    gmp    ip    validate    solution    human    license    relapse    treatment    heterogeneous    humanized    rna    total    pharma    sequence    precision    exclusive    tumours    anti    feasibility    days    efficacy   

Project "TK-NEO" data sheet

The following table provides information about the project.

Coordinator
TAKIS SRL 

Organization address
address: VIA DI CASTEL ROMANO 100
city: ROMA
postcode: 128
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-08-01   to  2020-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    TAKIS SRL IT (ROMA) coordinator 50˙000.00

Map

 Project objective

TK-NEO is a DNA-based Neoantigen Cancer Vaccine (NCV), for use as therapeutic vaccination in patients with locally advanced or metastatic solid tumours. NCVs are a new form of precision medicine and are a perfect clinical approach for highly heterogeneous tumors in patients with metastatic disease. Takis has developed and patented a unique method for production of patient-specific NCVs based on a 6-week process, from sequencing the specific tumour DNA, synthesis of the right DNA sequence for the specific tumour, delivery through a specific Electroporation (EP) technology used under exclusive license. The solution was proven at pre-clinical stage to reduce to zero a human lung cancer in humanized mice in 60 days and to increase the efficacy several fold with respect to alternative RNA and DNA based NCVs in protecting relapse and boosting immune responses as required for the maintenance of long-term anti-tumor immunity. The strategy to reach the market for TK-NEO is to license the IP of TK-NEO to a large pharma company, after completion of clinical validation trials to demonstrate the applicability and safety of the approach: phase I clinical trials in melanoma are targeted during SME Instrument project, while implementation of a GMP manufacturing to carry out phase II clinical trials and the implementation of the trials will require additional 5M investment. The Total Available Market is constituted by melanoma patients who underwent surgery and first chemotherapeutic treatment, who are estimated in the order of 30.000 patients per year combining EU and US. The objectives of the feasibility study are: 1) to validate the feasibility and the authorization process for the release tests, 2) to confirm investment, cost and pricing for TK-NEO, 3) to define a MoU with VC or with the final client (pharma) for the co-financing of the clinical development of customized TK-NEO and for future licensing.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TK-NEO" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TK-NEO" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

IMPACT (2019)

Improving DNA Analysis for Correct Healthcare

Read More  

Cortx (2019)

Intelligent debt recovery platform.

Read More  

TankSensor (2020)

Smart monitoring solution for better procurement and supply chain management - Speeding up chemical industry digitalization

Read More